Adjuvant Anal Imiquimod Therapy in Anal HPV-lesions: AdAM-trial — AdAM  

Anogenital Human Papillomavirus Infection Clinical Trial

Official title: Adjuvant Imiquimod Therapy to Reduce Recurrence Rate in Patients After Surgical Therapy of Anal HPV (Human Papilloma Virus)-Lesions

Status Not yet recruiting

Clinical Trial Summary

AdAM is a prospective, randomized, controlled, double-blinded, monocentric trial in patients receiving surgical therapy due to anal HPV infection.

Aim of the study is to evaluate efficacy of combination therapy (surgical therapy + topical Imiquimod-therapy). It is planned to include 200 patients.

100 patients receive surgical therapy+ topical Imiquimod therapy, 100 patients receive surgical therapy + topical Placebo therapy

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Anogenital Human Papillomavirus Infection
• Condyloma Anal
• Papillomavirus Infections

• NCT number: NCT03289260
• Study type: Interventional
• Source: Medical University Innsbruck
• Contact: Irmgard E Kronberger, MD
• Phone: 0043512504
• Email: irmgard.kronberger@i-med.ac.at
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: November 15, 2021
• Completion date: November 15, 2024